Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

1.

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group.

Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69.

PMID:
15920715
2.

Economic evaluation of donepezil in moderate to severe Alzheimer disease.

Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V; Donepezil MSAD Study Investigators Group.

Neurology. 2004 Aug 24;63(4):644-50.

PMID:
15326236
3.

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.

Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, Subbiah P; Donepezil MSAD Study Investigators Group.

J Am Geriatr Soc. 2003 Jun;51(6):737-44. Erratum in: J Am Geriatr Soc. 2003 Sep;51(9):1331.

PMID:
12757558
4.

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B; Donepezil MSAD Study Investigators Group.

Int Psychogeriatr. 2002 Dec;14(4):389-404.

PMID:
12670060
5.

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group.

Curr Med Res Opin. 2002;18(6):347-54.

PMID:
12442882
6.

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group.

Neurology. 2001 Aug 28;57(4):613-20. Erratum in: Neurology 2001 Dec 11;57(11):2153.

PMID:
11524468
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk